Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.170
-0.040 (-3.31%)
At close: Jun 2, 2026, 4:00 PM EDT
1.220
+0.050 (4.27%)
Pre-market: Jun 3, 2026, 4:46 AM EDT
Geron Revenue
Geron had revenue of $51.84M in the quarter ending March 31, 2026, with 30.89% growth. This brings the company's revenue in the last twelve months to $196.12M, up 68.64% year-over-year. In the year 2025, Geron had annual revenue of $183.88M with 138.83% growth.
Revenue (ttm)
$196.12M
Revenue Growth
+68.64%
P/S Ratio
3.83
Revenue / Employee
$760,136
Employees
258
Market Cap
750.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 183.88M | 106.89M | 138.83% |
| Dec 31, 2024 | 76.99M | 76.76M | 32,386.92% |
| Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
| Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
| Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
| Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
| Dec 31, 2019 | 460.00K | -606.00K | -56.85% |
| Dec 31, 2018 | 1.07M | 1,000.00 | 0.09% |
| Dec 31, 2017 | 1.07M | -5.10M | -82.72% |
| Dec 31, 2016 | 6.16M | -30.21M | -83.06% |
| Dec 31, 2015 | 36.37M | 35.22M | 3,054.47% |
| Dec 31, 2014 | 1.15M | -130.00K | -10.13% |
| Dec 31, 2013 | 1.28M | -1.43M | -52.64% |
| Dec 31, 2012 | 2.71M | 271.00K | 11.12% |
| Dec 31, 2011 | 2.44M | -1.13M | -31.57% |
| Dec 31, 2010 | 3.56M | 1.84M | 106.43% |
| Dec 31, 2009 | 1.73M | -1.08M | -38.42% |
| Dec 31, 2008 | 2.80M | -4.82M | -63.22% |
| Dec 31, 2007 | 7.62M | 4.35M | 132.59% |
| Dec 31, 2006 | 3.28M | -2.88M | -46.78% |
| Dec 31, 2005 | 6.16M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kura Oncology | 71.64M |
| CytomX Therapeutics | 35.54M |
| Evommune | 10.00M |
| Omeros | 9.89M |
| Odyssey Therapeutics | 2.98M |
| Allogene Therapeutics | 22.00K |
GERN News
- 1 day ago - Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 13 days ago - Geron Transcript: AGM 2026 - Transcripts
- 13 days ago - Geron Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 15 days ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Geron Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 21 days ago - Geron to present RWE study of RYTELO at EHA Congress - TheFly
- 21 days ago - First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 - GlobeNewsWire
- 27 days ago - Geron reports Q1 EPS (1c), consensus (2c) - TheFly